Digital Media Net - Your Gateway To Digital media Creation. News and information on Digital Video, VR, Animation, Visual Effects, Mac Based media. Post Production, CAD, Sound and Music
Categories: News

Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence

Novartis Pharmaceuticals Corporation to collaborate on development of new medical device software for earlier detection and intervention in cardiovascular disease

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence (AI)-powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use.

The collaboration will support Anumana’s efforts to implement AI-enabled diagnostic software that can detect signals from ECGs that humans cannot interpret. The collaboration will initially focus on cardiovascular diseases. Working with its expert partners from Mayo Clinic, Anumana will deploy novel solutions that use AI to analyze an ECG, a widely available, painless test that records the heart’s electrical signals to identify undiagnosed left ventricular dysfunction, or a weak heart pump, which can lead to heart failure. The AI will also screen for atherosclerotic cardiovascular disease, which can lead to heart attack and stroke. In addition, an evidence-based, digital point-of-care solution will be developed to guide in optimizing guideline-directed medical therapies with the aim to lower risk for potentially avoidable hospitalizations and cardiovascular death.

“Anumana technology is designed to help physicians identify patients who are at maximum risk of heart failure, long before they develop symptoms,” said Murali Aravamudan, CEO of Anumana. “Bringing together premier global organizations will allow us to expand access to best-in-class, AI-powered digital tools to benefit patients through earlier detection and intervention, when and where health care providers need it most.”

“Many heart diseases develop for years before signs and symptoms appear, but the first event may be life threatening,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “AI enables us to uncover hidden signals our bodies transmit to detect otherwise occult heart diseases, potentially years before symptoms appear. This collaboration has the potential to transform the use of a ubiquitous inexpensive test, the ECG, with the aim of democratizing disease detection and helping medical care teams to proactively manage heart disease ahead of time and prevent some clinical events from ever happening.”

“Cardiovascular disease is a widespread and multifactorial disease and, in order to mitigate its impact, we must look beyond therapeutic innovation and reimagine how we approach cardiovascular care,” said Victor Bulto, President, Novartis Innovative Medicines US. “Novartis is proud to collaborate with Anumana on innovative and data-driven solutions to better predict the risk of life-threatening heart disease, further driving forward our commitment to improving patient experiences and population health outcomes in this patient population.”

The Mayo Clinic Cardiology team, led by Dr. Friedman, pioneered the application of AI in cardiology and developed several algorithms based on millions of ECGs, including a low ejection fraction algorithm that received FDA Breakthrough Device Designation in 2019 and Emergency Use Authorization for COVID-19 in 2020. Further validating the technology, a recent study presented by Mayo Clinic used a modified version of Anumana’s 12-lead ECG algorithm to detect left ventricular dysfunction with single-lead ECGs in smartwatches. These algorithms are licensed to Anumana for development of clinical solutions and have been validated by over 30 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021. These software solutions are currently in development with each algorithm as a candidate for marketing authorization through an FDA De Novo request.

About Anumana

Anumana, an AI-driven health technology company and a portfolio company of nference and Mayo Clinic Platform, is harnessing industry-leading AI and translational science to decode the electrocardiogram as never before – as a deep predictive tool and biomarker of disease – empowering care providers to help patients early. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and are undergoing rigorous clinical trial validation. Anumana is developing AI-enabled ECG algorithms for real-world physician use, integrating point-of-care applications into existing workflows, thereby reducing costs and enhancing quality of life. Anumana’s AI-enabled tools can diagnose hidden conditions earlier than ever before. Anumana’s algorithms are investigational medical devices and have not yet received regulatory approval or clearance. For more information, visit anumana.ai and follow Anumana on LinkedIn & Twitter.

Contacts

Anumana

Andrea Sampson, Sampson Public Relations Group

asampson@sampsonprgroup.com
562.304.0301

Staff

Recent Posts

Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2023 Financial Results and Business Highlights

-- Second continuous year of gross profit growth -- -- Total SG&A expenses declined to…

3 hours ago

KCP Credit Analysis Now Available on the Bloomberg Terminal

NEW YORK--(BUSINESS WIRE)--#KBRA--KBRA Credit Profile (KCP), an industry-leading monthly surveillance platform covering more than 1,300…

3 hours ago

Mojo Vision Appoints Dr. Achin Bhowmik to the Board of Directors

President of Society for Information Display joins as independent board memberSARATOGA, Calif.--(BUSINESS WIRE)--Mojo Vision, the…

3 hours ago

Southern Glazer’s Wine & Spirits Announces Leaders for New Enterprise Data Center of Excellence

MIAMI & DALLAS--(BUSINESS WIRE)--Southern Glazer's Wine & Spirits (Southern Glazer's)—the world’s preeminent distributor of beverage…

3 hours ago

Rising Supply Draws in Some Buyers, Even as Housing Payments Soar 10% to All-Time High

Redfin reports there are more homes for buyers to choose from, with new listings posting…

3 hours ago

BNSF Railway builds upon safety record by utilizing virtual reality for training

FORT WORTH, Texas--(BUSINESS WIRE)--As the railway industry continues to power the American economy with sustainable…

7 hours ago